OssDsign - New clinical data strenghtens the case
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Nyhet

Nyheter Introduce

OssDsign - New clinical data strenghtens the case

Updated clinical data from 1,055 cranioplasty procedures 8-11% infection risk with competing implant technologies Important data points to promote further uptake Impressive updated post-market surveillance data OssDsign announced updated post-market surveillance data for its lead product – the cranial implant OssDsign Cranial PSI for 1,055 procedures (previously 670 procedures). At a median follow up time of 21 months (range, 0-70 months) 44 implants (4. 2%) have been explanted, i. e.

surgically removed due to complications. Only 2. 1% of the implants were explanted due to infections, which is a slight improvement from the previously reported 2.

4%. Furthermore, since most postoperative infections occur within 1-3 months, the majority of all patients (median follow-up time 21m) should be safe from such explantations going forward. Roughly 77% of the OssDsign Cranial implants were ordered by University hospitals with a high-level trauma unit, usually a sign of a new and groundbreaking technology being implemented.

Importantly, this constantly growing data set comes from 181 different hospitals across Europe, Asia and the US, showing that the outcomes are reproducible across different hospitals and countries. 2. 1% explantations due to infections is best-in-class As illustrated below, infection risk across competing materials for cranioplasty typically ranges between 8-11%.

Hence, it is one of the most common reasons for implant removal. These complications represent a significant economic burden. For example, the cost for managing a case of infection can cost ~USD 100K in the US.

This cost usually needs to be covered by the hospital’s budget, as most infections occur within the first three months after surgery, a period in which the hospital does not receive reimbursement from the insurers for corrective surgery. Important selling points for reimbursement and uptake We believe this is an important data point in terms of improving reimbursement and clinical up.

Artikeln i sin helhet
Denna källa har få eller inga artiklar bakom betalvägg
Läs hela artikeln

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om OssDsign

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!

STÄNG X
Populär sparapp – över 500 000 nedladdningar
Många och höga externa omdömen
Högst grad av diversifiering
Perfekt för regelbundet månadssparande
KOM IGÅNG

Nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 får automatiskt 50 procent rabatt på Optis avgift i 3 månader

Populära ekonominyheter

Om aktien OssDsign

Mer från Introduce

Vinnare & Förlorare

Börskollen använder själva TradingView för analys – prova du med (affiliatelänk)Analysera aktier här

Nyhetsbrev

Senaste nytt